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Abstract
It is important that patient-reported outcome (PRO) measures used to assess cancer therapies adequately capture the ben-
efits and risks experienced by patients, particularly when adverse event profiles differ across therapies. This study explores 
the case for augmenting preference-based utility measures to capture the impact of cancer treatment-related symptoms. 
Additional cancer treatment-related items could be specific (e.g., rash) or global. While specific items are easier to describe 
and understand, their use may miss rarer symptoms and those that are currently unknown but will arise from future medi-
cal advancements. The appropriate number of additional items, the independence of those items, and their impact on the 
psychometric properties of the core instrument require consideration. Alternatively, a global item could encompass all 
potential treatment-related symptoms, of any treatments for any disease. However, such an item may not be well understood 
by general public respondents in valuation exercises. Further challenges include the decision about whether to generate de 
novo value sets for the modified instrument or to map to existing tariffs. The fluctuating and transient nature of treatment-
related symptoms may be inconsistent with the methods used in conventional valuation exercises. Fluctuating symptoms 
could be missed by sub-optimal measure administration timing. The addition of items also poses double-counting risks. 
In summary, the addition of treatment-related symptom items could increase the sensitivity of existing utility measures to 
capture known and unknown treatment effects in oncology, while retaining the core domains. However, more research is 
needed to investigate the challenges, particularly regarding valuation.
Keywords Cancer · Oncology · Preference-based measure · Side effect · Adverse event
Introduction
For many years, chemotherapy, surgery and radiotherapy 
have been the most common forms of cancer treatment avail-
able. More recently, dramatic improvements have been made 
in the field of immunotherapy, which has become an impor-
tant therapeutic alternative and is now the first choice in 
many cases [1]. Immunotherapy enables the immune system 
to fight against cancer, infections, and other diseases. It has 
been shown to be effective in treating a range of advanced 
and metastatic cancers [2]. Recent successes have spurred a 
rapid increase in the number of immuno-oncology therapies 
being developed [3]. Traditional therapies for cancer, includ-
ing chemotherapy and radiotherapy, are in general poorly 
tolerated, being associated with a plethora of (often severe) 
toxicities ranging from hair loss to bruising and bleeding. 
The advent of immuno-oncology has led to its widespread 
adoption as a new standard of care for multiple tumour 
types, thanks not only to its efficacy but also its tolerability 
relative to conventional treatments. For example, a recent 
meta-analysis of 22 randomized clinical trials involving 
12,727 patients with solid organ malignancies concluded 
that patients receiving immunotherapy were less likely to 
develop severe treatment-related symptoms (also referred to 
as side effects, adverse effects, adverse events and treatment 
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risks) than those receiving traditional chemotherapy [4]. 
Nevertheless, as experience with immuno-oncology has 
grown, concerns have arisen regarding certain treatment-
related symptoms, including fatigue, diarrhoea, nausea and 
respiratory problems [5, 6]. Since candidate treatments 
tend to differ in terms of the severity of these effects and 
patients’ ability to tolerate them, it is important that any 
patient-reported outcome (PRO) measures used to assess 
the impact of treatments are able to adequately capture both 
their positive and negative effects [7].
The aim of this commentary paper is to examine the 
adequacy of existing generic and condition-specific pref-
erence-based measures for capturing important outcomes 
in cancer, and to explore the case for modifying or adding 
items to existing measures to capture the impact of treat-
ment-related symptoms. This commentary paper provides a 
targeted overview and discussion of the literature and cur-
rent issues, with the view to encouraging further discussion 
within the health economics and outcomes research field, 
and to informing future PRO development and refinement 
in the field of oncology.
The paper is structured as follows. First, the types of PRO 
measures used in cancer are described. The suitability of 
descriptive systems for capturing health effects of treatment 
is then discussed, with reflections on how existing generic 
measures could be adapted, and on how condition-specific 
measures have dealt with the issue. Next, challenges relat-
ing to valuation, capturing transient events, and modeling 
are explored. Finally, future steps towards addressing these 
challenges are summarized.
Generic and condition‑specific preference‑based 
measures used in cancer
PROs can be delineated in a variety of ways as measures of 
health/health-related quality of life, notably as generic or 
condition-specific measures, and as preference-based or non-
preference-based measures (note that the term ‘preference-
based measure’ has been criticized as these measures are 
also used in applications where social preference weights are 
not relevant; ‘preference-accompanied measure’ has been 
suggested as an alternative [8]). There has been tremendous 
interest in preference-based measures in recent years due to 
their relevance in economic evaluations, as they can facili-
tate the calculation of quality-adjusted life years [9].
The EQ-5D, Health Utilities Index Mark 3 (HUI3), and 
SF-6D are three of the most prominent generic preference-
based measures. A review of the psychometric properties 
of these instruments by Longworth et al. [10] showed that 
of the three, EQ-5D was by far the most commonly used 
in oncology, with 71 of the 98 studies reviewed report-
ing EQ-5D utility data (compared to 24 and three studies 
reporting HUI3 and SF-6D data, respectively). While there 
is evidence that EQ-5D is valid and reliable in many can-
cers [10, 11], there are concerns that this and other such 
generic measures are not sensitive enough and inevitably 
miss domains that are important in capturing the benefits 
and risks of new cancer treatments [12, 13].
Condition-specific measures are, therefore, preferred in 
some situations because by focusing on the condition of 
interest, they cover important dimensions that generic meas-
ures may miss, and can be more sensitive for a given dimen-
sion [14]. It is important to note that generic and disease-
targeted measures are often used for different purposes. In 
cancer, examples of condition-specific measures include the 
European Organization for Research and Treatment of Can-
cer Quality of Life Questionnaires (EORTC QLQ) [15], the 
MD Anderson Symptom Inventory (MDASI) suite of meas-
ures [16] and the Functional Assessment of Cancer Therapy 
(FACT) family of instruments [17]. Since these measures 
have been developed specifically for use in cancer, they tend 
to offer greater content validity than generic measures within 
the oncology setting [18], when used for the intended pur-
poses. On the other hand, for the purpose of serving as a 
health status descriptor relevant for evaluation in the general 
population, the content validity of QLQ-C30/FACT-G (and, 
therefore, QLU/FACT-8D) can be questioned.
However, the use of condition-specific measures poses 
problems in achieving cross-program comparability [19]. 
Many cancer-specific measures are not preference based or 
amenable to valuation. This means that they cannot be used 
to calculate quality-adjusted life years (QALYs), thereby 
precluding their use in cost-utility analysis. As an alternative 
to developing an entirely new cancer-specific preference-
based measure, researchers have developed mapping func-
tions that allow the conversion of outcomes from a non-pref-
erence-based measure to the values for a preference-based 
measure [10, 20]. The ISPOR Good Practices Task Force 
Report on mapping to estimate health-state utility from non-
preference-based outcome measures provides methodologi-
cal recommendations to analysts undertaking such studies 
[21]. Further recommendations on best practices for report-
ing the results of utility mapping studies have been provided 
in the MAPS (MApping onto Preference-based measures 
reporting Standards) statement [22]. However, mapping is 
unsuitable in situations where there is little overlap in con-
tent between the two measures, and it should not be used 
when the target preference-based measure is considered 
inappropriate.
Another approach is to take existing non-preference-
based measures and reduce them so as to make them ame-
nable to valuation [23]. This usually involves using psycho-
metric criteria to select a subset of items from the existing 
measure and to analyze the performance of the candidate 
items. Relevant methods include factor analysis (a technique 
for identifying structurally independent dimensions with low 
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correlation between each other), Rasch analysis (a technique 
that uses logistic models to convert categorical responses to 
points on a continuous scale), and assessments of validity 
and responsiveness. For example, the EORTC Quality of 
Life Utility Measure (EORTC QLU-C10D) is a health state 
classification system based on the larger EORTC QLQ-Core 
30 (C30) cancer-specific quality of life questionnaire [24]. 
The QLU-C10D, which succeeded the EORTC 8D [25], 
comprises 10 dimensions, linked to 13 items selected from 
the 30 items of the QLQ-C30. The QLU-C10D has been val-
ued using discrete choice experiments, and several national 
value sets have been reported [26–29]. The QLU-C10D 
valuation studies included a duration attribute to enable the 
anchoring of values onto the QALY scale [30]. Similarly, 
the FACT-8D is an eight-dimension preference-based meas-
ure derived from the FACT–General (FACT-G) question-
naire [31]. However, this approach may not be sufficient as 
many existing non-preference-based based measures such 
as the EORTC QLQ-C30 and the FACT-G were developed 
when chemotherapy was the dominant treatment paradigm 
in oncology. Since this time, the treatment landscape has 
evolved significantly and, therefore, many items in these 
measures may not be fully valid.
Yet even preference-based condition-specific measures 
may be problematic as they involve naming the condition 
(which can lead to bias [32]), lack a common upper anchor, 
and often miss impact on possible co-morbidities [33]. Valu-
ation study respondents may exaggerate the importance of 
problems associated with the condition underpinning the 
health states under evaluation compared to other conditions 
(thereby leading to relatively large utility decrements) due 
to the psychological tendency to focus on what is placed in 
front of them [19], though this finding has not always been 
observed in the QLU-C10D valuation studies [26–29]. These 
concerns may undermine consistency in making compari-
sons between QALYs calculated using different measures. 
While some measures include domains representing known 
treatment-related symptoms (the QLU-C10D includes 
fatigue, appetite and nausea dimensions, for example [24]), 
unknown and less common side effects tend to be missed. 
Looking to the future, the effects of emerging innovative 
oncology treatments may be different from those of the 
chemotherapeutic regimens of past eras or from current 
immunotherapy options, and the cancer-specific measures 
previously developed may no longer be well suited to cap-
ture the array of health impacts.
Health technology assessment (HTA) agencies requiring 
cost-utility analyses generally prefer generic measures over 
condition-specific measures to promote consistency and 
comparability across appraisals [34]. However, preference-
based condition-specific measures are sometimes accepted 
by HTA agencies in cases where there is evidence that the 
use of a generic measure is inappropriate, e.g., due to poor 
psychometric performance in the relevant patient group [35]. 
For example, in a National Institute for Health and Care 
Excellence (NICE) appraisal of fluocinolone acetonide intra-
vitreal implant for the treatment of chronic diabetic macu-
lar oedema, the manufacturer collected quality of life data 
using a vision-specific questionnaire, the NEI-VFQ-25 [36]. 
NICE’s appraisal committee accepted that a disease-specific 
instrument was likely to be more responsive to changes of 
relevance to patients than the Institute’s preferred generic 
measure, the EQ-5D.
Adaptation of existing measures
While it is common to include both generic and condition-
specific measures in a clinical trial data collection strategy 
(indeed, some generic measures have been designed to be 
used alongside other, more detailed measures) [37], it is 
often desirable to limit the number of instruments in a given 
study to reduce patient, investigator and operational burden. 
A potential compromise is to develop an adapted version of a 
generic measure for use in specific diseases. This notion has 
parallels with the extension of condition-specific measures 
for use in specific subtypes of the disease. For example, the 
FACT-G is considered appropriate for use in patients with 
any form of cancer, and is complemented by variants that 
include questions specific to particular sites/tumors (e.g., 
FACT-C for colorectal cancer) [38, 39]. The EORTC QLQ 
and MDASI instrument groups also have modules covering 
symptoms relevant for specific patient populations, intended 
to complement the core questionnaires or items.
One way of adapting a generic measure is by modify-
ing the descriptive system to include additional dimensions 
of health. In the context of the EQ-5D, such dimensions 
have been described as ‘bolt-on’ items. Such an approach 
could improve the performance of the measure in certain set-
tings, whilst retaining the general structure and conceptual 
framework underpinning the original measure and achieving 
better consistency with any utility values associated with 
the original measure. Existing research has examined the 
impact of expanding the EQ-5D to include bolt-on dimen-
sions such as cognition [40], psoriasis (skin irritation and 
self-confidence) [41], sleep [42], vision, hearing, tiredness 
[43] and respiratory problems [44], amongst others. Beyond 
the EQ-5D, Brazier et al. have examined the impact of add-
ing a pain and discomfort dimension to the AQL-5D, an 
asthma-specific preference-based measure [45]. Cancer has 
been a key area in which preference-based approaches have 
been applied to disease-specific measures, thereby offering 
some insight into opportunities for bolt-ons [46].
Figure 1 shows when the adaptation of an existing generic 
measure may be justified—namely, if the generic measures 
fail to pick up important aspects of health and show poor 
psychometric properties in the relevant patient populations, 
 K. K. Shah et al.
1 3
and if measures specific to the condition of interest either 
do not exist or are otherwise inadequate [47]. It should be 
noted that these are necessary but not sufficient conditions 
for adapting a measure. Ultimately, the adaptation should 
improve the psychometric properties of the measure, i.e., it 
should address existing concerns about its content or face 
validity amongst the relevant patient population, and should 
matter to people to the extent that it would make a differ-
ence to utility values (though there are challenges involved 
in assessing this; see below) and ultimately to cost-effec-
tiveness estimates. Psychometric methods such as principal 
component analysis can be used to identify gaps and identify 
candidate bolt-on dimensions for measures [48]. Principal 
component analysis involves examining a matrix of item 
correlations to reduce the information into a smaller set of 
components, with high intercorrelations implying that items 
are measuring the same latent component. Components can 
then be selected based on their eigenvalues, which represent 
the relative share of total variance accounted for by each 
component [49].
Capturing treatment‑related symptoms
The QLU-C10D comprises multiple concepts, including 
items relating to functioning (physical, role, social and emo-
tional) and disease-related symptoms such as pain. It also 
includes items that capture common side effects of cancer 
treatments, such as nausea and bowel problems. However, 
it lacks a general (or ‘global’) treatment-related symptoms 
item. According to King et al. [24], this reflects the con-
vention that attributes in utility instruments typically rep-
resent specific domains of health. By contrast, amongst the 
FACT measures, both the general and more specific ques-
tionnaires contain a global side effects item (FACIT GP5) 
which asks respondents to indicate the extent to which they 
are ‘bothered by side effects of treatment’ using a five-point 
scale. This is consistent with the US Food and Drug Admin-
istration recommendation that the adverse consequences of 
treatment are measured separately from treatment effective-
ness [50].
The absence of a global side effects item means that 
measures such as the QLU-C10D may miss the full range of 
possible treatment-related symptoms, including for example, 
immune-related side effects such as breathing problems, rash 
and impacts on physical appearance [6] that do not corre-
spond to any of the measure’s existing items (though short-
ness of breath is included in the larger QLQ-C30 question-
naire). It is practically difficult to identify an encompassing 
set of symptoms when using specific items rather than a 
global item [51]. Scientific understanding of immune-related 
side effects is evolving as novel classes of immuno-oncology 
therapies come to market. As experience with these agents 
grows, it is plausible that further important treatment-related 
symptoms may be identified in the future that are not well 
captured by existing items in these measures.
As noted above, an alternative to such cancer-specific 
measures would be to use a generic preference-based meas-
ure and to add items designed to improve its performance 
in oncology. Treatment-related symptoms could be cap-
tured via a global item or one or more specific items. A 
global item would allow the capturing of all possible side 
effects, including those that are less common or not cur-
rently known. This could allow researchers to more effec-
tively compare new treatments versus standard of care by 
adding information on the severity of their respective side 
effect profiles. However, it may be difficult to frame a global 
treatment-related symptoms item in a way that reflects how 
patients themselves think about and describe their health and 
treatment. Patients may not use terms like ‘treatment-related 
symptoms’ (though phrases such as ‘bothered by the effects 
Fig. 1  Questions to consider when determining the case for adapting an existing generic measure
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of your treatment’ may overcome this concern), and indeed 
may not know whether a particular health problem they are 
experiencing is a symptom of their disease or a consequence 
of their treatment. In other disease areas, single-item ratings 
of side effects have not been recommended due to concerns 
about their lack of reliability and sensitivity to change [52]. 
On the other hand, items describing specific side effects, 
such as breathing problems, are likely to be better under-
stood, but adding only one or two items may be insufficient 
given the large variety of symptoms associated with cancer 
therapy in practice. Adding a large number of items may 
be undesirable as this introduces the risk that the brevity 
and core structure of the original instrument will be lost, 
i.e., the more dimensions that are added, the more likely 
it will be that the additional dimensions double-count the 
same construct (double-counting is also a concern for the 
global item approach due to overlap between the perceived 
adverse effects of treatment and impacts on core domains, 
particularly domains related to discomfort). A key challenge 
is to find a balance between the two competing options to 
describe side effects.
Valuation issues
Condition-specific measures can in principle be valued using 
stated preference methods, as demonstrated by the recently 
published suite of QLU-C10D value sets [26–29]. How-
ever, if a generic measure is preferred, then adding items 
to existing measures may overcome this problem by plac-
ing the condition-specific element within the context of a 
broader health status measure, thereby potentially lessen-
ing the impact of focusing effects. This would necessitate 
the generation of a new value set for the augmented meas-
ure [44]. Not only would this be a very expensive process, 
but the new value set could be discordant with the existing 
value sets, e.g., the rank order of existing parameters could 
change. While the possibility of such findings should not 
deter research in this area, it would undoubtedly introduce 
challenges for HTA agencies who may be faced with pos-
sible ‘gaming’ due to the choice of multiple value sets, each 
with different properties. A potential solution has been sug-
gested by Yang et al. [53], who explored the feasibility of 
using parameters from existing EQ-5D-5L value sets to pre-
dict values when new items are added. These were used as 
fixed parameters in modeling the bolt-on data, with a scale 
parameter introduced to capture the effects of adding the 
bolt-on item. The new items are valued as an additive or 
multiplicative deviation from the existing tariff. However, 
the evidence base supporting this approach is limited, and 
complications may arise if the new items interact with and 
affect the relative weightings of the existing items.
Further, health state valuations are conventionally 
derived from the preferences of the general population 
[54], as opposed to current patients. It is not clear whether 
a global item describing treatment-related symptoms would 
be understood by such individuals, particularly if they have 
never before experienced an unexpected adverse effect of 
treatment. Lack of familiarity with treatment burden may 
have contributed to general population samples placing rela-
tively low weighting on specific symptom items in the QLU-
C10D. A vignette valuation approach may help to provide 
the necessary context, though this is associated with other 
limitations such as inflexibility and challenges in incorporat-
ing into economic models [14].
A further issue in valuation relates to possible bias and 
focusing effects when specifying that symptoms are related 
to treatment. Valuation survey respondents may place a dif-
ferent amount of emphasis on symptoms if they are told that 
these are caused by treatment rather than by the disease, 
even if the impact of the symptoms on patients’ health and 
lives is the same irrespective of their cause. This may be an 
argument for favoring specific items that are not framed as 
being treatment related.
Challenges of implementation: capturing transient 
events
Treatment side effects may be impactful, but are often short 
lived or variable over the course of treatment. Such fluctua-
tions in health pose measurement challenges. Sanghera and 
Coast [55] note that when health fluctuates, standard meas-
urement and analytic approaches may not be suitable due to 
recall periods and the timing of assessment. This is due to 
a phenomenon known as ‘recall bias’ in which the length 
of recall periods can introduce error or bias into clinical 
trials. For example, if the period is too long, it may lead to 
cognitive distortion in memory of an event (e.g., an event 
being perceived as less severe as when it was experienced); 
if too short, it may not allow enough time for an outcome to 
occur [56, 57].
The EQ-5D asks respondents to self-report their health 
status ‘today’, so the health state reported could differ 
depending on whether or not the symptoms of treatment are 
being experienced on the day of questionnaire completion 
(though this also applies to the core dimensions, and can be 
addressed by optimizing the timing of measurement; see 
below). Questionnaires with longer recall periods may run 
into other issues (such as the FACT-G which asks about the 
‘past seven days’) since it is unclear whether respondents 
should consider their average health or worst health expe-
riences over that period [17]. The QLQ-C30 mixes recall 
periods, with some items framed in the present tense (e.g., 
‘Do you have any trouble […]’) and other items—including 
those covering common side effects—covering a one-week 
recall period [15].
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Fixed-duration recall periods may be problematic in the 
context of health state valuation, particularly using tech-
niques such as time trade-off which posit that the health 
state in question is experienced for a specified duration that 
differs from the measurement recall period (conventionally 
10 years in many valuation protocols [58]). For this reason, 
when valuing the preference-based QLU-C10, all 10 dimen-
sions are framed in the present tense, in contrast to the cor-
responding QLQ-C30 items. The use of fixed health state 
durations, like 10 years, in valuation may be problematic 
for side effects and other episodic or intermittent changes 
in health, irrespective of the recall period used in the meas-
ure. EQ-5D valuation studies, for example, require valua-
tion survey respondents to imagine that they will experience 
the specified health problems (e.g., moderate problems in 
walking about) for 10 years, with no variation in the level 
of those problems throughout that period [58]. Although 
some respondents may question whether such a scenario is 
realistic, it is at least straightforward to specify and compre-
hend. It is less clear how a health state involving occasional 
or fluctuating levels of problems with treatment-related 
symptoms (or indeed fluctuating disease symptoms) would 
be described over a 10-year period. Some researchers have 
attempted to find solutions for valuing profiles in which 
health varies over time [59, 60]. An issue encountered is that 
respondents tend to neglect information about the amount of 
time spent in symptomatic states.
Related to recall period is the issue of timing of assess-
ment. Patients may or may not be experiencing side effects 
at the point of questionnaire completion (which suggests that 
longer recall periods, more frequent collection, or event-
driven questionnaire completion may be appropriate). The 
side effects of certain cancer treatments may be predictable. 
For example, if the adverse effects of chemotherapy typically 
occur during the first week of treatment and recede by the 
next administration of treatment, then measurement on the 
day of treatment would miss the impact of these side effects 
[55]. To capture fully the impact of side effects—whether 
via a bolt-on dimension or not—it is important to optimize 
the timing of measurement in clinical trials to reflect fluctua-
tion patterns that are known and predictable [50]. Advances 
in the electronic collection of PRO data are expected to facil-
itate greater flexibility in this regard, allowing patients to 
self-report their health status at time points that are relevant, 
and not merely operationally convenient. If it is possible to 
capture PROs when symptoms occur, this would lessen the 
recall bias associated with retrospective data collection.
Challenges of implementation: modeling
If important side effects are omitted from a given PRO meas-
ure, and therefore from the health state utility values associ-
ated with that measure, analysts may adjust the utility data to 
capture the impact of these side effects in economic models. 
Indeed, the ISPOR Good Practices Task Force Report on the 
identification, review, and use of health state utilities in cost-
effectiveness models [61] explicitly recommends assessing 
“the extent to which the utility effects of important adverse 
events are captured by the data used to estimate a model’s 
non-adverse-event HSUs [health state utilities]” (p.273).
In practice, disutility values relating to treatment-related 
symptoms are typically sought from the literature and 
applied by subtracting the disutility from the utility value 
associated with the health state of interest or multiplying a 
weighting associated with the adverse event with the value 
of the health state of interest. These approaches risk double-
counting if the main utility values already partially reflect 
the impact of those symptoms because the measure used 
captures them implicitly (this kind of double-counting issues 
is likely to occur when using any measure that describes 
symptoms). Further, the disutility values are often sourced 
or synthesized from data from multiple studies, which may 
be of variable methodological quality that used different, 
non-comparable valuation methods, and may not all have 
examined exactly the same side effect as the one being incor-
porated in the model. In some cases, disutility values for 
side effects are omitted from the model due to the lack of 
relevant data [62].
The inclusion of specific treatment-related symptoms 
(core or additional) items could help mitigate these issues. 
Notwithstanding the valuation issues described above, 
the valuation of the treatment-related symptoms would be 
combined with the valuation of the other health outcomes, 
thereby ensuring consistency in the methods used to gener-
ate the utility data. However, in order for such an item to 
demonstrate useful psychometric properties, the framing of 
the items and the frequency and timing of the data collection 
would need to be optimized so that the (sometimes transient) 
symptoms are not systematically missed at the point of ques-
tionnaire completion. It would also need to be demonstrated 
that the incidence rates of these side effects are sufficiently 
high, and their expected impact on quality-adjusted life years 
is sufficiently great, so as to justify their inclusion in the 
measure.
Limitations
This commentary paper does not present any data or analy-
ses that could be used to examine empirically some of the 
conjectures and discussion points presented. The points 
raised were drawn from the literature and the authors’ own 
knowledge and experiences, but no systematic review of the 
literature was undertaken. We are not aware of any existing 
reviews of studies to augment preference-based measures 
in general, but refer readers to a review of studies of bolt-
ons specifically for the EQ-5D [63]. This commentary paper 
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has focused on oncology, largely due to the importance of 
treatment-related symptoms when assessing and comparing 
immuno-oncology therapies. Some of the points raised may 
not be generalizable to other disease areas. However, the 
schematic shown in Fig. 1 is not specific to oncology and 
can be applied to any condition. Questions such as whether 
a global or specific treatment-related symptoms item is pre-
ferred are relevant in disease areas beyond oncology. For 
example, in systematic lupus erythematosus, researchers 
responsible for developing the LupusPRO opted to include 
items describing specific treatment-related symptoms as well 
as a general item capturing ‘bothersome side effects’ [64].
Conclusions
When a preference-based measure of health is required, an 
additional layer of complexity is cast upon the acknowledged 
strengths and limitations of generic and disease-specific 
measures. Adapting existing generic preference-based meas-
ures by adding treatment-related symptoms items potentially 
improves their sensitivity to health-related changes/differ-
ences in cancer patients, whilst retaining a degree of consist-
ency with the original measures. This may be preferable to 
relying on cancer-specific preference-based measures, which 
are less useful for comparability across appraisals, and do 
not themselves always capture these symptoms satisfacto-
rily. It may also be preferable to continually developing new 
measures to address the shortcomings of existing ones. Such 
an approach would facilitate a more complete assessment of 
competing treatments with adverse event profiles that may 
differ in important ways. It could also reduce the sometimes 
problematic need for separate adjustment for adverse events 
in economic models (though some aspects of these events, 
such as survival outcomes and costs, would still need to be 
modeled separately from the health-related quality of life 
data).
Several challenges and research questions remain. While 
a global treatment-related symptoms item could encapsu-
late a range of symptoms for a host of current and future 
treatments (and could even cover symptoms associated with 
treatments for conditions other than cancer), it is not clear 
how well such an item would be understood by patients, 
particularly if they cannot distinguish between the symp-
toms of their condition and the side effects of treatment. In 
addition, it is unclear whether general public respondents 
in a study seeking to obtain utility values for the adapted 
measure would be able to comprehend valuing a global item 
that does not refer to specific side effects. Both issues war-
rant further research prior to adding global treatment-related 
symptoms items to existing preference-based measures.
It is also unclear what the appropriate recall period would 
be for treatment-related symptoms, many of which are 
transient or fluctuate in way that differ from the symptoms 
of the disease. These issues need investigating in further 
research in order to assess the case for adding treatment-
related symptoms items to an established measure such as 
the EQ-5D.
Further research is also required into the optimal 
approach for valuing these additional items. Methods that 
avoid the need for newly developed value sets bespoke to 
each new item (and associated measure) are desirable on 
efficiency grounds and from the perspective of HTA agen-
cies who require a degree of consistency in their methods 
of assessment and decision-making. Research to date has 
suggested that adding an item may affect the valuation of 
the core items of the instrument, so the additional impact 
on utility may not be simply additive [10]. Further testing 
of the approach proposed by Yang et al. [53], and alterna-
tive methods such as the use of discrete choice experiments 
to assess preferences for the additional items relative to the 
core dimensions of the instrument, would be beneficial.
Any adaptation of an existing measure, including devel-
opment of new treatment-related symptoms items, would 
require a full assessment of psychometric properties to 
assess if the adaptation offers an improvement to the status 
quo. Further, the adapted instrument should also have an 
impact on associated utility values to offer an improvement. 
This may not always be the case, as demonstrated by Yang 
et al. who found that the inclusion of a sleep item did not 
have a significant impact on utilities derived for EQ-5D-3L 
health states [42].
The era of immuno-oncology increasingly reveals that 
current approaches to measuring the impact of cancer treat-
ment-related symptoms on utility values are sub-optimal. 
This commentary paper has outlined alternative approaches 
that could be adopted to better capture these impacts for cur-
rent and future treatments. Further research is needed to test 
the feasibility of these approaches and assess their impact 
on decision-making.
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